Investigational antifungal agents

Pharmacotherapy

Volumn 21, Issue 8 SUPPL. 2, 2001, Pages

  Ernst, E J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; ITRACONAZOLE; NIKKOMYCIN; NYSTATIN; POSACONAZOLE; RAVUCONAZOLE; SORDARIN DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; MINIMUM INHIBITORY CONCENTRATION; REVIEW;

EID: 0034897490     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.12.165s.34509     Document Type: Review

References (65)

1. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida sp isolates from HIV-infected patients
2. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America
3. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
4. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
5. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report
6. In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies
7. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients
8. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus sp to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)
9. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against bloodstream isolates of Candida sp
10. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
11. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
12. International surveillance of bloodstream infections due to Candida species in the European SENTRY program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
13. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
14. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
15. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
16. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole
17. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida
18. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
19. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
20. In vitro evaluation of voriconazole against some clinically important fungi
21. Ravuconazole: Multiple ascending oral dose study in healthy subjects
22. SCH56592: Rising multiple-dose safety, tolerance, and pharmacokinetic evaluation in healthy volunteers
23. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man
24. A double-blind, randomized multicenter trial of voriconazole versus fluconazole for the treatment of esophageal candidiasis in immunocompromised adults
25. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
26. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease
27. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: A randomized international multicenter trial
28. The effect of voriconazole on the pharmacokinetics of cyclosporin
29. Drug interactions between voriconazole and phenytoin
30. Effect of omeprazole on the pharmacokinetics of voriconazole
31. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole
32. SCH56592: Bioavailability of an oral suspension relative to a solid dosage form in healthy volunteers
33. Posaconazole equivalent to fluconazole in the treatment of oropharyngeal candidiasis
34. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy
35. Safety and tolerance of posaconazole (SCH56592) in patients with nonmeningeal disseminated coccidioidomycosis
36. Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients
37. Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects
38. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
39. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
40. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida sp
41. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
42. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
43. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide
44. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents
45. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
46. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
47. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
48. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
49. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents
50. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations or azoles
51. Single dose caspofungin pharmacokinetics in healthy elderly subjects
52. A phase I study of caspofungin evaluating the potential for drug interaction with itraconazole, the effect of gender, and the use of a loading regimen
53. Phase II, randomized, open-label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis
54. Phase I dose optimization study for V-echinocandin
55. Sordarins: A new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts
56. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans
57. Anti-Candida activity of the sordarin derivatives GW471552, GW47558, GW506540, GW531920 and GW560849: Effect of endpoint role and incubation time on MIC
58. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis
59. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis
60. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model
61. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis
62. Antibiotics that inhibit fungal cell wall development